[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"graves-ophthalmopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:graves-ophthalmopathy":382},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,56,89,121,153,182,210,232,263,290,315,337,361],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100640670","prospective-observational-study-of-smartphone-based-ai-self-monitoring-during-non-surgical-treatment-for-thyroid-eye-disease-thyroscope-100640670",false,"NCT07623993","Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE)","Prospective Observational Study of Smartphone-Based Self-Monitoring Using an Artificial Intelligence Solution During Non-Surgical Treatment for Thyroid Eye Disease","THYROSCOPE-TED","Inclusion Criteria:\n\n* Adults aged 19 years or older with a clinical diagnosis of thyroid eye disease (TED).\n* Patients with TED scheduled to initiate active non-surgical treatment, including but not limited to intravenous methylprednisolone, oral corticosteroids, radiotherapy, or biologic therapy.\n* Able to undergo baseline clinical assessment prior to initiation of the planned treatment course and expected routine follow-up evaluation during treatment, including an end-of-treatment assessment.\n* Able and willing to use their own smartphone to complete the study application-guided symptom questionnaire and capture standardized frontal facial images throughout the study period.\n* Willing to perform at least weekly home-based image capture and symptom reporting during the treatment course.\n* Able to participate in routine in-person follow-up visits and expected to provide at least two clinic-matched assessments, including baseline and at least one post-baseline assessment.\n* Voluntarily provides written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Severe eyelid deformities, facial deformities, or other facial\u002Fperiocular conditions that may interfere with standardized image acquisition or reliable AI-based image analysis.\n* Unable to use the study application or smartphone-based image capture procedure adequately for protocol-required self-monitoring.\n* Undergoing or planning to undergo surgical treatment for TED as the primary treatment modality during the study period.\n* History of ocular, eyelid, or orbital surgery within 3 months prior to enrollment.\n* Any medical, psychiatric, cognitive, or other condition that, in the investigator's judgment, may compromise protocol compliance, study participation, or data integrity.\n* Any other condition that the investigator judges to make the patient inappropriate for participation.","ALL","22 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","This prospective observational study evaluates the feasibility and clinical utility of a smartphone-based artificial intelligence (AI) self-monitoring system in adults with thyroid eye disease (TED) undergoing non-surgical treatment. Eligible participants will use their own smartphones and the study application (Glandy) to perform at least weekly home monitoring consisting of a symptom questionnaire (diplopia, pain on visual analog scale) and a standardized frontal facial photograph. AI-derived outputs (Glandy CAS, Glandy EXO, Glandy LID) obtained at routine clinic visits will be compared with standard clinician assessments (CAS total score, Hertel exophthalmometry, MRD1\u002FMRD2). AI outputs will not be used for real-time clinical decision-making during the study.",[25,26,27],"Thyroid Eye Disease (TED)","Graves Ophthalmopathy","Thyroid Associated Ophthalmopathies",[29,30,31,32,33,34,35,36,37,38,39,40,41,42],"Thyroid eye disease","TED","Graves orbitopathy","Artificial intelligence","Smartphone","Self-monitoring","Clinical Activity Score","CAS","Exophthalmometry","MRD1","MRD2","Remote monitoring","Digital health","Telemedicine","NOT_YET_RECRUITING","2026-05-28",{"date":46,"type":47},"2026-06-03","ACTUAL",{"date":49,"type":21},"2026-07-01",{"date":51,"type":21},"2027-12-31",{"name":53,"class":54},"THYROSCOPE INC.","INDUSTRY",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":55},"100637519","phase-2-teprotumumab-n01-versus-methylprednisolone-after-urgent-orbital-decompression-for-dysthyroid-optic-neuropathy-100637519","NCT07594912","Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy","A Single-Center, Prospective, Randomized, Open-Label, Parallel-Group Study Comparing Sequential Teprotumumab N01 With Intravenous Methylprednisolone After Urgent Orbital Decompression in Patients With Dysthyroid Optic Neuropathy","Inclusion Criteria:\n\n* Able and willing to provide written informed consent.\n* Age 18 to 65 years.\n* Clinical diagnosis of thyroid eye disease (TED) with dysthyroid optic neuropathy (DON). Diagnosis of DON must meet both of the following criteria:\n\n  1. Visual dysfunction not explained by other causes, such as decreased best-corrected visual acuity, visual field defect, abnormal color vision, or relative afferent pupillary defect.\n  2. Imaging evidence of orbital apex crowding, optic nerve compression, or optic nerve stretching.\n* The study eye meets the criteria for urgent orbital decompression, defined as either of the following:\n\n  1. Poor response after rescue intravenous methylprednisolone for the current dysthyroid optic neuropathy episode, with a cumulative methylprednisolone-equivalent dose of no more than 3.0 g, defined as no improvement or continued deterioration of visual function within 1 to 2 weeks.\n  2. Contraindication to glucocorticoids or investigator judgment that direct urgent mechanical decompression is required.\n* Thyroid function is normal or mildly abnormal before enrollment, with free triiodothyronine (FT3) and free thyroxine (FT4) within 50% above or below the normal reference range when possible.\n* Alanine aminotransferase (ALT) no more than 1.5 times the upper limit of normal, aspartate aminotransferase (AST) no more than 3 times the upper limit of normal, and serum creatinine no more than 1.5 times the upper limit of normal.\n* For participants with diabetes mellitus, hemoglobin A1c (HbA1c) less than 9.0% and stable antidiabetic treatment within 60 days before enrollment.\n* For women of childbearing potential, a pregnancy test must be negative before enrollment.\n* Participants of reproductive potential agree to use effective contraception during the study and for 90 days after the last dose of study treatment.\n* Able and willing to comply with study treatment and follow-up procedures.\n\nExclusion Criteria:\n\n* Orbital decompression surgery within 6 months before screening.\n* Bilateral dysthyroid optic neuropathy requiring urgent bilateral orbital decompression at baseline.\n* Cumulative preoperative methylprednisolone-equivalent dose greater than 3.0 g for the current dysthyroid optic neuropathy episode.\n* Systemic glucocorticoid treatment for non-thyroid eye disease within 3 months before screening with cumulative methylprednisolone-equivalent dose of 1.0 g or greater.\n* Tocilizumab or other systemic immunosuppressive treatment within 3 months before screening, or rituximab within 6 months before screening.\n* Orbital radiotherapy within 3 months before screening.\n* Previous treatment with teprotumumab.\n* Other ocular diseases that may significantly affect visual function assessment, including glaucomatous optic neuropathy, macular disease, severe cataract, or non-thyroid eye disease optic neuropathy.\n* Irreversible optic nerve damage in the study eye with very low potential for visual recovery, as judged by the investigator.\n* History of definite inner ear disease or clinically significant hearing impairment.\n* Severe cardiovascular disease.\n* Severe hepatic or renal disease.\n* Active infection or clinically significant infectious disease, including active hepatitis, HIV infection, syphilis, or active tuberculosis.\n* Active gastrointestinal ulcer.\n* Clinically significant abnormal blood test results, including white blood cell count less than 4.0 × 10\\^9\u002FL, platelet count less than 80 × 10\\^9\u002FL, hemoglobin less than 110 g\u002FL in males or less than 100 g\u002FL in females.\n* History of malignancy judged by the investigator to be unsuitable for enrollment.\n* Pregnancy or breastfeeding.\n* Known allergy to monoclonal antibodies, methylprednisolone, or any study drug excipient.\n* Uncontrolled diabetes mellitus or any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.","18 Years","65 Years",{"count":66,"type":21},60,"INTERVENTIONAL",[69],"PHASE2","This study aims to evaluate the efficacy and safety of sequential Teprotumumab N01 compared with intravenous methylprednisolone (IVMP) after urgent orbital decompression in patients with dysthyroid optic neuropathy (DON).",[72,26,73],"Thyroid Eye Disease, TED","Optic Neuropathy",[75,76,77,78,29],"Dysthyroid optic neuropathy","Orbital decompression","Teprotumumab N01","Intravenous methylprednisolone pulse","2026-05-17",{"date":81,"type":47},"2026-05-19",{"date":83,"type":21},"2026-08",{"date":85,"type":21},"2028-04",{"name":87,"class":88},"Sun Yat-sen University","OTHER",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":67,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":55},"100635072","phase-2-tofacitinib-for-glucocorticoid-resistant-moderate-to-severe-thyroid-eye-disease-100635072","NCT07547930","Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease","A Single-Arm, Open-Label, Exploratory Study of Tofacitinib in Patients With Glucocorticoid-Resistant or Intolerant Moderate-to-Severe Active Thyroid Eye Disease","TOFA-GO","Inclusion Criteria:\n\n1. Age and Gender: Male or female participants aged 18 to 75 years (inclusive).\n2. Diagnosis: Clinical diagnosis of Graves' orbitopathy (GO) consistent with EUGOGO criteria.\n3. Severity: Moderate-to-severe GO as defined by EUGOGO guidelines (impact on daily life, but not sight-threatening).\n4. Activity: Active disease, defined as a Clinical Activity Score (CAS) \\>=3 points (on the 7-point scale).\n5. Refractory Status (Must meet ONE of the following):Glucocorticoid-Resistant: Failure to respond (no significant improvement in proptosis or CAS) after receiving a cumulative dose of at least 3g of intravenous methylprednisolone (or equivalent).Glucocorticoid-Intolerant: Documented contraindications to high-dose systemic glucocorticoids (e.g., uncontrolled diabetes mellitus, severe osteoporosis, glaucoma, severe psychiatric disorders) or history of severe adverse events leading to discontinuation.\n6. Thyroid Function: Euthyroid or mild hypothyroidism\u002Fhyperthyroidism maintained on stable antithyroid drugs or thyroxine replacement therapy for at least 4 weeks prior to baseline.\n7. Contraception: Women of childbearing potential must agree to use effective contraception during the study period and for at least 4 weeks after the last dose of the study drug.\n8. Consent: Willing and able to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* 1.Sight-Threatening Disease: Presence of Dysthyroid Optic Neuropathy (DON) or severe corneal breakdown requiring immediate surgical intervention.\n\n  2.Chronic\u002FInactive Disease: Fibrotic or burnout stage of GO with a Clinical Activity Score (CAS) \\\u003C 3.\n\n  3.Prior Orbital Treatment:Orbital radiotherapy at any time.Orbital surgical decompression at any time.Strabismus surgery or eyelid surgery within 3 months prior to baseline.\n\n  4.Concomitant Immunomodulation: Use of other biologic agents (e.g., Teprotumumab, Rituximab, Tocilizumab) within 3 months prior to baseline.\n\n  5.Active Infection Risk (Critical for JAK Inhibitors):Active tuberculosis (TB) or untreated latent TB.Active or chronic Hepatitis B or Hepatitis C infection.Human Immunodeficiency Virus (HIV) infection.History of disseminated herpes zoster or herpes simplex.Any severe active infection requiring hospitalization or IV antibiotics within 4 weeks of baseline.\n\n  6.Thrombosis Risk: History of venous thromboembolism (VTE), including deep vein thrombosis (DVT) or pulmonary embolism (PE), or known coagulation disorders.\n\n  8.Malignancy: History of any malignancy within the past 5 years (except adequately treated basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix).\n\n  9.Laboratory Abnormalities:Absolute Neutrophil Count (ANC) \\\u003C 1.0 \\*10\\^9\u002FL and\u002For Absolute Lymphocyte Count (ALC) \\\u003C 0.5 \\*10\\^9\u002FL and \u002For Hemoglobin \\\u003C 90 g\u002FL and\u002For AST or ALT \\> 2\\* Upper Limit of Normal (ULN) and\u002For Estimated Glomerular Filtration Rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m²","75 Years",{"count":99,"type":21},8,[69],"Thyroid Eye Disease (TED), also known as Graves' orbitopathy, is an autoimmune condition that causes inflammation and tissue expansion behind the eyes, leading to bulging eyes (proptosis), double vision, and pain. Currently, intravenous glucocorticoids (steroids) are the standard first-line treatment. However, approximately 20-30% of patients do not respond to steroids, or cannot tolerate their side effects.\n\nThis study aims to evaluate the safety and efficacy of Tofacitinib, an oral medication known as a Janus kinase (JAK) inhibitor, as a rescue therapy for these difficult-to-treat cases. Tofacitinib works by blocking specific signaling pathways (JAK-STAT) that drive inflammation and fibrosis in the eye socket. In this study, patients with moderate-to-severe active TED who are resistant to or intolerant of steroids will receive Tofacitinib tablets (5 mg twice daily) for 24 weeks. The researchers will assess whether the treatment can effectively reduce eye bulging and improve clinical activity scores.",[72,26,103],"Graves Orbitopathy",[105,106,107,108,109,110],"Tofacitinib","Refractory Thyroid Eye Disease","Graves' Orbitopathy","JAK Inhibitor","Steroid-resistant","Glucocorticoid-resistant","RECRUITING","2026-04-28",{"date":114,"type":47},"2026-04-29",{"date":116,"type":47},"2026-04-24",{"date":118,"type":21},"2027-12-30",{"name":120,"class":88},"The First Affiliated Hospital of Xiamen University",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":128,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":67,"phases":131,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":55},"100623755","statin-and-vitamin-d-treatment-in-patients-with-thyroid-eye-disease-100623755","NCT07400757","Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease","The Role of Statin and Vitamin D for the Treatment of Thyroid Eye Disease","Inclusion Criteria:\n\n* Adults aged 20 years or older\n* Diagnosis of active thyroid eye disease with a Clinical Activity Score (CAS) of 3 or higher\n* Low-density lipoprotein cholesterol (LDL-C) level of 100 mg\u002FdL or higher\n\nExclusion Criteria:\n\n* Prior orbital radiotherapy or orbital surgery for thyroid eye disease\n* Use of statins or high-dose vitamin D supplementation (greater than 400 IU per day) within 3 months prior to enrollment\n* Pregnancy\n* Severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) less than 30 mL\u002Fmin\u002F1.73 m²","20 Years",{"count":130,"type":21},120,[132],"NA","The goal of this clinical trial is to learn whether statin therapy and vitamin D supplementation can modify disease activity in patients with active thyroid eye disease. The study will also evaluate the safety of these treatments. The main questions it aims to answer are:\n\n* Does statin therapy change disease activity, as measured by changes in the Clinical Activity Score (CAS) and proptosis?\n* Does vitamin D supplementation change disease activity in patients with active thyroid eye disease?\n* Does combined treatment with statin and vitamin D produce different effects compared with either treatment alone or standard care?\n* What adverse events occur during treatment?\n\nResearchers will compare four groups: standard care alone, statin therapy plus standard care, vitamin D supplementation plus standard care, and combined statin and vitamin D therapy plus standard care.\n\nParticipants will:\n\n* Be randomly assigned to one of four treatment groups\n* Receive the assigned treatment for 24 weeks\n* Attend clinic visits for clinical assessments and blood tests at baseline and at 24 weeks\n* Be followed through medical record review for up to three years after completion of the intervention",[72,26],[136,26,137,138,139,140,141,142,143,35],"Thyroid Eye Disease","Statin","Vitamin D","Atorvastatin","Autoimmune Disease","Inflammation","Randomized Controlled Trial","Factorial Design",{"date":145,"type":47},"2026-04-30",{"date":147,"type":47},"2026-02-24",{"date":149,"type":21},"2032-07-15",{"name":151,"class":152},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":160,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":55},"100629903","systemic-inflammation-thyroid-autoimmunity-and-neuroretinal-changes-in-graves-disease-100629903","NCT07480720","Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease","Relationship Between Systemic Inflammation, Thyroid Autoimmunity, and Neuroretinal Structures in Graves Disease","Inclusion Criteria:\n\n* Age ≥ 18 years\n\nDiagnosis of Graves' disease (for the patient group)\n\nNo known thyroid disease in healthy control participants\n\nAvailability of optical coherence tomography (OCT) measurements and laboratory data\n\nTime interval between OCT examination and blood sampling ≤ 10 days\n\nExclusion Criteria:\n\n* Presence of glaucoma, optic neuropathy, or retinal vascular diseases\n\nMacular diseases, uveitis, or severe refractive error (high myopia \\>6 diopters)\n\nDiabetic retinopathy\n\nHistory of previous intraocular surgery\n\nHistory of active infection, malignancy, or systemic inflammatory disease\n\nPoor-quality OCT measurements (segmentation errors or low signal strength)",true,{"count":162,"type":21},100,"This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will be reviewed. Optical coherence tomography (OCT) measurements, including macular thickness and peripapillary retinal nerve fiber layer (RNFL) thickness, will be analyzed. Laboratory parameters such as complete blood count-derived inflammatory indices, C-reactive protein, thyroid function tests, and thyroid autoantibodies will also be recorded. The study will compare neuroretinal parameters between healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy, and will investigate potential associations between systemic inflammation, thyroid autoimmunity, and neuroretinal structural changes.",[165,26],"Graves Disease",[167,168,169,170,171,172],"Graves disease","Thyroid autoimmunity","Systemic inflammation","Optical coherence tomography","Retinal nerve fiber layer","Graves ophthalmopathy","2026-03-14",{"date":175,"type":47},"2026-03-18",{"date":177,"type":47},"2026-03-01",{"date":179,"type":21},"2026-05-01",{"name":181,"class":88},"Elazıg Fethi Sekin Sehir Hastanesi",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":160,"sex":189,"minAge":63,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":193,"conditions":194,"keywords":198,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":55},"100491380","exploring-immunological-markers-associated-with-mental-fatigue-in-graves-disease-100491380","NCT05678374","Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease","Exploring Immunological Markers in Blood and Cerebrospinal Fluid Associated With Mental Fatigue in Euthyroidism After Graves' Disease- a Cross Sectional Study","Inclusion Criteria\n\n* If patient: Graves' disease with positive TSH-receptor antibodies and thyroid hormones above the upper reference limit at diagnosis\n* Diagnosis15 to 60 months ago. If recidive both episodes must have occurred within 15 months to 60 months.\n* Thyroid hormones within normal range without anti thyroid drugs\n* If control: No thyroid disease\n* Patient and control without mental fatigue: Mental Fatigue Score ≤8 (cut off 10.5)\n* Patient with mental fatigue: Mental Fatigue Score \\>13 and debut of symptoms of mental fatigue in parallel with debut of Graves' disease, without other obvious cause\n\nExclusion Criteria\n\n* Person unable to follow protocol\n* Multiple sclerosis, myalgic encephalomyelitis\u002Fchronic fatigue syndrome, any other neurological disease\n* Traumatic brain injury with unconsciousness\n* Other disease strongly associated with fatigue\n* Pregnancy and breast-feeding\n* On-going or recent systemic treatment with steroids\n* Radioiodine therapy within the last 18 months","FEMALE","72 Years",{"count":192,"type":21},180,"Mental fatigue occurs in many diseases and the reasons are mostly unknown. The investigators hypothesize that remaining mental fatigue after restored hyperthyroidism in Graves' disease is an autoimmune complication. The aim of this study is to explore immunological markers possibly associated with mental fatigue in Graves' disease, which the investigators plan to validate in another study (ImmunoGraves wp 2).\n\nUsing a cross-sectional study design, mental fatigue is scored using a questionnaire to find 60 patients with and 60 without mental fatigue 15-60 months after diagnosis of Graves disease. The patients and 60 thyroid healthy controls without mental fatigue are assessed for thyroid hormones, quality of life, anxiety and depression, self-evaluated stress, coping strategies, eye symptoms and background variables. SciLifeLab in Stockholm, the national facility for autoimmune profiling, has pre-set large arrays including 42000 human proteins. Serum and cerebrospinal fluid will be separately pooled and analysed for a subgroup of patients with or without mental fatigue and for a subgroup of the control group. Proteins that preferably bind to antibodies in sera and\u002For cerebrospinal fluid from Graves' patients with mental fatigue in comparison to non-mental fatigue patients, will be screened against the Human Protein Atlas and the Allen brain map to identify those proteins that are expressed in the brain. Antibodies at higher concentration in the mental fatigue pools compared to the group without mental fatigue will be selected for further analyses on an individual level in the whole cohort together with antibodies targeting g-protein coupled receptors, thyroid autoantibodies, cytokines and biomarkers indicating organic and structural nerve damage.",[165,26,195,196,197],"Mental Fatigue","Autoimmune Diseases","Thyroid Diseases",[199,200],"Biomarkers","Cerebrospinal fluid in Graves' disease","2025-09-23",{"date":203,"type":47},"2025-09-29",{"date":205,"type":47},"2019-10-01",{"date":207,"type":21},"2028-12-20",{"name":209,"class":152},"Vastra Gotaland Region",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":67,"phases":219,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":55},"100340139","early-phase-1-bimatoprost-as-a-treatment-for-graves-orbitopathy-100340139","NCT03708627","Bimatoprost as a Treatment for Graves' Orbitopathy","The Role of Bimatoprost in Graves' Periorbitopathy","Inclusion Criteria: Graves' Ophthalmopathy with Exophthalmos\u002FProptosis -\n\nExclusion Criteria: Active Graves Disease, Currently pregnant, Taking Steroids\n\n\\-",{"count":218,"type":21},3,[220],"EARLY_PHASE1","Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease",[26],"2025-07-14",{"date":225,"type":47},"2025-07-17",{"date":227,"type":47},"2017-11-01",{"date":229,"type":21},"2031-07-01",{"name":231,"class":88},"Johns Hopkins University",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":67,"phases":241,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":262},"100524715","phase-2-extension-study-of-two-doses-of-linsitinib-in-subjects-with-active-moderate-to-severe-thyroid-eye-disease-ted-100524715","NCT06112340","Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","Inclusion Criteria:\n\n* Subject who completed the 24-week double-mask period of VGN-TED-301 and are proptosis non-responders (\\\u003C 2 mm reduction in proptosis in the study eye) at Week 24 of VGN-TED-301 study or proptosis responders at Week 24 who relapse during the Follow-Up period of VGN-TED-301\n* Subject has not received any treatment for TED since Week 24 of VGN-TED-301\n* Subjects must be euthyroid with the participant's baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine \\[FT4\\] and free triiodothyronine levels \\[FT3\\] \\\u003C50% above or below the normal limits) at Baseline. Every effort should be made to correct mild hypo- or hyperthyroidism promptly and maintain the euthyroid state for the duration of the clinical trial\n* Does not require immediate ophthalmic surgery, radiotherapy to orbits or other ophthalmological intervention at the time of Baseline and is not planning for any such treatment during the course of the study\n\nExclusion Criteria:\n\n* The exclusion criteria of protocol VGN-TED-301 also apply to this extension study.",{"count":240,"type":21},75,[69,242],"PHASE3","The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.",[136,103,245,246,247,26,197,248,249,250,251,252],"Endocrine System Diseases","Eye Diseases","Thyroid Associated Ophthalmopathy","Orbital Diseases","Proptosis","IGF1R","Exophthalmos","Hashimoto","2025-02-24",{"date":255,"type":47},"2025-02-25",{"date":257,"type":47},"2023-10-11",{"date":259,"type":21},"2026-06",{"name":261,"class":54},"Sling Therapeutics, Inc.",2,{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":97,"enrollmentInfo":270,"targetDuration":4,"studyType":67,"phases":272,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":262},"100448952","phase-4-hydroxychloroquine-in-mild-graves-orbitopathy-100448952","NCT05126147","Hydroxychloroquine in Mild Graves' Orbitopathy","A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Mild Graves' Orbitopathy","Inclusion Criteria:\n\n* Mild GO according European Group on Graves' orbitopathy (EUGOGO) guidelines diagnosed by endocrinologist and ophthalmologist.\n* No previous treatment of GO except for eyedrops\n* Euthyroidism (normalized free T4 and TSH) for at least 2 months. If radioactive iodine is used for hyperthyroidism, euthyroidism needs to be achieved for at least 6 months.\n\nExclusion Criteria:\n\n* Moderate-to-sever or sight-threatening GO according to EUGOGO guidelines diagnosed by endocrinologist and ophthalmologist.\n* Pregnancy\n* Drug or alcohol abuse\n* Unable to comply with the study protocol\n* Unable to obtain informed consent\n* Use of hydroxychloroquine or systemic steroid within 3 months prior to enrollment\n* History of side effects of hydroxychloroquine\n* History of retinopathy\n* Renal dysfunction (estimated glomerular filtration rate (eGFR) \\\u003C 60ml\u002Fmin)\n* Hepatic dysfunction (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 2 x upper limit)\n* Anemia (hemoglobin (Hb) \\\u003C 10g\u002Fdl)\n* Neutropenia (absolute neutrophil count \\\u003C 100\u002FuL)\n* Thrombocytopenia (platelet (PLT) \\\u003C 150000\u002FuL)\n* Glucose-6-phosphate dehydrogenase (G6PD) deficiency\n* Porphyria cutaneous tarda\n* Allergy to 4-aminoquinoline",{"count":271,"type":21},108,[273],"PHASE4","This study is aimed to investigate the effect of hydroxychloroquine in patients with mild Graves' orbitopathy (GO).",[26],[277,278,279,280,281],"Graves' ophthalmopathy","Graves' disease","Hydroxychloroquine","Orbital volumetry","GO-QoL questionnaire","2025-02-23",{"date":255,"type":47},{"date":285,"type":47},"2022-03-21",{"date":287,"type":21},"2026-12-31",{"name":289,"class":88},"National Taiwan University Hospital",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":67,"phases":299,"briefSummary":300,"conditions":301,"keywords":303,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":55},"100295884","phase-3-treatment-of-gravesophthalmopathy-with-simvastatin-go-s-100295884","NCT03131726","Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)","Inclusion Criteria:\n\n1. Age 18-70 years\n2. Active mild to moderate with at least one sign of mild GO (NO SPECS class 2a and b) with reference to Colour Atlas at EUGOGO website (www.eugogo.eu). Exophthalmos up to 24 mm with a disease duration of \\\u003C18 months (as recorded by the patient)\n3. Graves´ disease with clinical and laboratory euthyroidism after stopping treatment with anti thyroid drugs (ATD), or 2 months treatment with ATD, or euthyroid 6 months after treatment with radioiodine, or euthyroid after total thyroidectomy. Clinical and laboratory euthyroidism is defined as normal fT4, fT3 and TSH below the upper limit of the local reference interval and no clinical symptoms or signs of hyperthyroidism. L-thyroxine is used to achieve euthyroidism during the study period.\n\nExclusion Criteria:\n\n1. Pregnancy or breast-feeding\n2. Previous treatment of Graves´ ophthalmopathy\n3. Severe Graves ophthalmopathy requiring corticosteroid treatment, retrobulbar irradiation, orbital decompression surgery\n4. Current or previous treatment with simvastatin or other statins (within 3 months)\n5. Allergy (skin rash or systemic reactions) to statins\n6. Congestive heart failure\n7. Renal insufficiency (glomerular filtration rate \\\u003C60 ml\u002Fmin)\n8. ASAT or ALAT \\> 2.5 times the upper limit of the local laboratory\n9. Alcoholism as judged by local criteria\n10. Coagulopathy including treatment with warfarin or new oral anti-coagulation drugs\n11. Previous or current gastric ulcer\n12. Inflammatory bowel disease diabetic retinopathy or nephropathy\n13. Trauma within 10 days","70 Years",{"count":298,"type":21},80,[242],"In an investigator initiated multicenter trial (Malmö, Odense, Århus) the investigators aim at evaluating activity of Graves´ophthalmopathy (GO) and progress to severe GO in patients with mild to moderate Graves´ ophthalmopathy treated with simvastatin or no treatment.",[26,247,302],"Thyroid Associated Orbitopathy",[304,305],"simvastatin","diclofenac","2024-09-23",{"date":308,"type":47},"2024-09-25",{"date":310,"type":47},"2018-01-26",{"date":312,"type":21},"2028-03-30",{"name":314,"class":88},"Lund University",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":67,"phases":325,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":55},"100561330","modified-orbital-decompression-in-the-treatment-of-moderate-to-severe-graves-ophthalmopathy-100561330","NCT06588764","Modified Orbital Decompression in the Treatment of Moderate-to-severe Grave's Ophthalmopathy","Modified Deep Lateral Wall Decompression and\u002For Deep Medial Wall Decompression for Moderate-to-severe Grave's Ophthalmopathy: a Prospective Study","Inclusion Criteria:\n\n1. EUGOGO\u002FNOSPECS grade was moderate-to-severe thyroid associate ophthalmopathy;\n2. CAS≤3 score;\n3. stable thyroid function for at least 6 months;\n4. able and willing to participate in clinical trials and ensure regular follow-up;\n\nExclusion Criteria:\n\n1. any uncontrollable clinical problems (severe mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant tumors);\n2. B-ultrasound or CT, MRI found other diseases causing exophthalmos (intraorbital space occupying lesion, inflammatory pseudotumor, neurofibroma, etc.);\n3. uveitis, glaucoma, high myopia, diabetic retinopathy and other eye diseases\n4. those who were considered by the researchers to be excluded","80 Years",{"count":324,"type":21},50,[132],"To investigate the efficacy and safety of modified deep lateral wall decompression and\u002For medial wall decompression for Moderate-to-severe Grave's Ophthalmopathy.",[26,328],"Surgery","2024-09-05",{"date":331,"type":47},"2024-09-19",{"date":333,"type":21},"2024-09",{"date":335,"type":21},"2026-01",{"name":87,"class":88},{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":64,"enrollmentInfo":344,"targetDuration":4,"studyType":67,"phases":346,"briefSummary":347,"conditions":348,"keywords":349,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":4},"100555286","phase-4-a-randomized-clinical-trial-of-intravenous-methylprednisolone-with-2-protocols-in-patients-with-graves-orbitopathy-100555286","NCT06510114","A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy","Comparison of Two Intravenous Methylprednisolone Protocols in Patients With Graves Orbitopathy: a Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age 18-65 years old;\n2. diagnosed as thyroid associated ophthalmopathy by using Bartley criteria，Moderate to severe (EUGOGO grade), with CAS≥3 points;\n3. Thyroid function normally lasts for more than 2 months, with oral antithyroid drugs or thyroid surgery, or six months after iodine-131 treatment;\n4. without receiving immunosuppressive therapy for thyroid eye disease before.\n\nExclusion Criteria:\n\n(1) severe cardiac, liver and renal insufficiency (2) acute or chronic viral hepatitis or tuberculosis (3) optic neuropathy (4) received immunosuppressive and glucocorticoid therapy for any reason within the past 3 months",{"count":345,"type":21},150,[273],"Intravenous glucocorticoid (IVGC) is an accessible and effective therapy for Graves orbitopathy (GO); the 4.5-g weekly protocol is well studied, but many details of treatment protocols need to be clarified. The goal of this trial is to compare the efficacy and safety of weekly and daily protocol of IVGC in GO. Researchers will compare daily protocol to weekly protocol to see if daily protocol works to treat GO.",[26],[350,26,351],"Hyperthyroidism","glucocorticoid","2024-07-15",{"date":354,"type":47},"2024-07-19",{"date":356,"type":21},"2024-07",{"date":358,"type":21},"2026-12",{"name":360,"class":88},"Third Affiliated Hospital, Sun Yat-Sen University",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":160,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":369,"conditions":370,"keywords":371,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":55},"100537249","the-effect-of-teprotumumab-on-thyroid-eye-disease-and-thyroid-dysfunction-100537249","NCT06275373","The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction","Teprotumumab","Inclusion Criteria:\n\n* only DOD beneficiaries\n* adult patients 18 years of age or older\n* adult patients with proptosis, ocular\u002Forbital pain, diplopia, lid\u002Forbital edema, or lid\u002Forbital erythema associated with autoimmune thyroid disease\n\nExclusion Criteria:\n\n* Patients with evidence of compressive optic neuropathy necessitating urgent orbital decompression or external beam radiation\n* patients with a history of uncontrolled diabetes mellitus\n* patients with a history\u002Fdiagnosis of uncontrolled inflammatory bowel disease\n* patients under age 18 years\n* patients who are pregnant or trying to become pregnant.",{"count":162,"type":21},"This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid\u002Forbital edema, or lid\u002Forbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).",[136,26,165],[29,172,167],"2024-02-16",{"date":374,"type":47},"2024-02-23",{"date":376,"type":47},"2021-05-12",{"date":378,"type":21},"2027-12-12",{"name":380,"class":381},"Walter Reed National Military Medical Center","FED","Graves' Ophthalmopathy"]